Theravance Sales Jump 83 Percent
Theravance Biopharma (NASDAQ:TBPH), a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company’s revenue (GAAP) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million. Net income (GAAP) of $54.8 million was reported, reflecting a non-recurring gain from the sale of the TRELEGY royalty asset. Excluding one-time gains, operational profitability remained limited. The period showed robust commercial progress in YUPELRI but highlighted a shift toward a more concentrated revenue base and reliance on upcoming milestones for future growth.
Source: Analyst estimates for the quarter provided by FactSet.
Theravance Biopharma develops and commercializes respiratory therapies and medicines for rare diseases. Its main product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD), marketed through a partnership with Viatris. The company also pursues clinical programs in neurogenic orthostatic hypotension (nOH), notably through the late-stage development of ampreloxetine, a norepinephrine reuptake inhibitor for patients with Multiple System Atrophy (MSA).
Source Fool.com
